These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

697 related items for PubMed ID: 18520983

  • 1. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E, CoSa Study Group.
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [Abstract] [Full Text] [Related]

  • 2. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 3. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 26; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 4. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.
    J Neurol Sci; 2004 Jul 15; 222(1-2):13-9. PubMed ID: 15240190
    [Abstract] [Full Text] [Related]

  • 5. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
    Cocco E, Marchi P, Floris G, Mascia MG, Deriu M, Sirca A, Mamusa E, Lai M, Mura M, Mallarini G, Marrosu MG.
    Funct Neurol; 2006 Jul 15; 21(3):145-9. PubMed ID: 17049133
    [Abstract] [Full Text] [Related]

  • 6. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
    Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B, EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group.
    J Neurol Sci; 2005 Dec 15; 239(1):67-74. PubMed ID: 16169561
    [Abstract] [Full Text] [Related]

  • 7. [Interferon-beta 1a in relapsing-remitting multiple sclerosis. First report of a Mexican population].
    León C, Violante A, Arriada N, Santana HR, Corona T.
    Rev Neurol; 2005 Dec 15; 31(11):1019-22. PubMed ID: 11190865
    [Abstract] [Full Text] [Related]

  • 8. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA, Rivera VM.
    Curr Med Res Opin; 2010 Apr 15; 26(4):827-38. PubMed ID: 20121658
    [Abstract] [Full Text] [Related]

  • 9. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 15; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 10. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
    Mult Scler; 2010 Jan 15; 16(1):68-77. PubMed ID: 19995846
    [Abstract] [Full Text] [Related]

  • 11. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
    Baum K, O'Leary C, Coret Ferrer F, Klímová E, Procházková L, Bugge J, BRIGHT Study Group.
    Mult Scler; 2007 Nov 15; 13(9):1153-60. PubMed ID: 17967843
    [Abstract] [Full Text] [Related]

  • 12. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.
    Clin Ther; 2010 Jun 15; 32(6):1061-6. PubMed ID: 20637960
    [Abstract] [Full Text] [Related]

  • 13. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.
    Patti F, Pappalardo A, Florio C, Politi G, Fiorilla T, Reggio E, Reggio A.
    Acta Neurol Scand; 2006 Apr 15; 113(4):241-7. PubMed ID: 16542163
    [Abstract] [Full Text] [Related]

  • 14. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 15; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 15. [Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)].
    Hernandez-Perez MA, Grupo de Investigadores Del Estudio PARALEN.
    Rev Neurol; 2005 Nov 15; 48(10):505-8. PubMed ID: 19434583
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb 15; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 17. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
    Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA.
    Mult Scler; 2010 May 15; 16(5):588-96. PubMed ID: 20167591
    [Abstract] [Full Text] [Related]

  • 18. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O, Casado V, Moral E, Alonso-Magdalena L, Martínez-Yélamos A, Martínez-Yélamos S, Martín-Ozaeta G, Arbizu T.
    Eur Neurol; 2008 May 15; 60(6):279-84. PubMed ID: 18824855
    [Abstract] [Full Text] [Related]

  • 19. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.
    Oger J, Francis G, Chang P, PRISMS Study Group.
    J Neurol Sci; 2005 Oct 15; 237(1-2):45-52. PubMed ID: 16026803
    [Abstract] [Full Text] [Related]

  • 20. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study.
    Ghezzi A, Immunomodulatory Treatment of Early Onset MS (ITEMS) Group.
    Neurol Sci; 2005 Dec 15; 26 Suppl 4():S183-6. PubMed ID: 16388355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.